Stem cell like memory T cells: A new paradigm in cancer immunotherapy

Clin Immunol. 2022 Aug:241:109078. doi: 10.1016/j.clim.2022.109078. Epub 2022 Jul 15.

Abstract

Stem cell like memory T (TSCM) cells have emerged as the apex of memory T cell differentiation for their properties of self-renewal and replenishing progenies. With potent long-term persistence, proliferative capacity and antitumor activity, TSCM cells were thought to be the ideal candidate for cancer immunotherapies. Several strategies have been proposed, such as manipulations of cytokines, metabolic factors, signal pathways, and T cell receptor signal intensity, to induce more TSCM cells in vitro, in the hope that they could reach a clinical order of magnitude to provide more long-lasting and effective anti-tumor effects in vivo. In this review, we summarized the differentiation characteristics of TSCM cells and strategies to generate more TSCM cells. We focused on their roles and application in the cancer immunotherapy especially in adoptive cell transfer therapy and cancer therapeutic vaccines, and hopefully provided clues for future understanding and researches.

Keywords: Adoptive cell transfer; Cancer immunotherapy; Cancer therapeutic vaccines; Memory T cells; Stem cell like memory T cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes
  • Cancer Vaccines*
  • Humans
  • Immunologic Memory
  • Immunotherapy, Adoptive
  • Memory T Cells
  • Neoplasms* / therapy
  • Stem Cells

Substances

  • Cancer Vaccines